LPL Financial
ACTU

LPL Financial’s Actuate Therapeutics ACTU Stock Holding History

LPL Financial’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3K Sell
11,965
-1,000
-8% -$2.32K ﹤0.01% 6135
2026
Q1 		$35.5K Hold
12,965
– – ﹤0.01% 5817
2025
Q4 		$79.3K Sell
12,965
-3,250
-20% -$22.3K ﹤0.01% 5647
2025
Q3 		$108K Sell
16,215
-2,490
-13% -$18.1K ﹤0.01% 5499
2025
Q2 		$114K Buy
+18,705
New +$163K ﹤0.01% 5240

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

LPL Financial's ACTU Position: Q2 2026 in Review

LPL Financial reduced its Actuate Therapeutics (ACTU) stake by 7.7% in Q2 2026, selling an estimated $2.32K and leaving 11,965 shares worth $18.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6135.

LPL Financial first reported a position in ACTU in Q2 2025 and has held it in 5 quarters since. The position peaked at $114K in Q2 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • LPL Financial held 11,965 shares of Actuate Therapeutics worth $18.3K as of Q2 2026.
  • LPL Financial sold 1,000 Actuate Therapeutics shares in Q2 2026, an estimated $2.32K.
  • Actuate Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #6135 holding.
  • LPL Financial first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • LPL Financial's Actuate Therapeutics position peaked at $114K in Q2 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.